PISCES Trial: The study is a multi-centre, 2×2 factorial, superiority randomised controlled trial (RCT) to test (1) securements (Securement device vs. integrated securement device), and (2) dressings (chlorhexidine-disc vs. no disc) for peripherally inserted central catheters (PICCs) in Cancer patients. Principal Site Investigator: N Marsh
PICNIC trial: This study is a multicentre, parallel group, superiority RCT comparing the clinical- and cost- effectiveness of the (i) anti-thrombogenic (AT [Endexo®] and (ii) chlorhexidine gluconate PICCs, to (iii) conventional polyurethane PICCs in paediatric and adult patients. Principal Site Investigators: P, Harris, N Marsh
Midline trial: this RCT is comparing midline catheters and peripheral intravenous catheters (PVC) for the prevention of insertion failure and post-insertion failure; and to generate pilot data to support a larger, definitive trial. Principal Investigator: N Marsh
Optimum trial: A multi-centre RCT comparing an integrated PVC system against current practice a non-integrated system. Principal Site Investigator: N Marsh
Vascular Access Passport: this is a consumer-led innovation to implement improvements in central venous access device management in the cancer care population. Principal Site Investigators: E Larsen, N Marsh, N Roberts
Cocoa Trial: this RCT is comparing positive and neutral needleless connectors for the prevention of PVC failure. Principal Investigators: N Marsh, E Larsen, C O’Brien, Davies K, McLeod K, Booker C
Adorn trial: This RCT is comparing an anti-microbial disc to no-disc for infection prevention in central venous access devices in ICU. Principal Investigator: N Marsh
SURF Trial: This study aims to test the feasibility of evaluating perforated versus non-perforated peripheral catheter design. Cancer care patients requiring injection of contrast via PIVC for a Computerised Tomography (CT) scan for diagnosis or staging of malignant oncology or haematology conditions, will be enrolled.